Intellia Therapeutics, Inc.

Disease Roundup: Four Gene-Editing Candidates in...

Sep. 20, 2023

There are currently four clinical-stage gene-editing candidates in clinical trials for sickle cell disease, which affects millions of people worldwide...

Intellia Therapeutics Announces Positive Phase 1...

Jul. 5, 2023

Intellia Therapeutics recently shared new positive clinical data from the ongoing Phase 1 trial of NTLA-2002 in hereditary angioedema (HAE). NTLA-2002...

Intellia Therapeutics Gets FDA Green Light to...

Mar. 15, 2023

Intellia Therapeutics recently announced that the FDA has cleared an Investigational New Drug application for NTLA-2002, a single-dose in vivo CRISPR...

Gene-Edited T Cells Treat Leukaemia and Solid...

May. 23, 2022

Researchers from Italy’s Ospedale San Raffaele Scientific Institute, in collaboration with Intellia Therapeutics, have used CRISPR to introduce...

Clinical update: FDA Upgrades Status for Two...

Mar. 16, 2022

This week's update includes news about two gene-edited therapies for cancer. Allogene Therapeutics' ALLO-316 has been granted Fast Track Designation...

First Patient Dosed in CRISPR Trial for Acute...

Mar. 9, 2022

Intellia Therapeutics recently announced that the first patient had been dosed in its Phase 1/2a CRISPR trial for acute myleoid leukaemia (AML). The...

Clinical Update: CRISPR Therapy for Transthyretin...

Mar. 2, 2022

In this week's update, we provide news about Intellia Therapeutics' and Regeneron's ongoing Phase 1 trial for NTLA-2001 in transthyretin amyloidosis....

CRISPR Clinical Trial Roundup: Rare Diseases

Feb. 16, 2022

In this week's clinical trial update, we summarise the ongoing in vivo CRISPR clinical trials for three distinct rare genetic diseases: hereditary...